APOL1 Bi- and Monoallelic Variants and Chronic Kidney Disease in West Africans. New England Journal of Medicine , 2024; DOI: 10.1056/NEJMoa2404211 Cite This Page : ...

Understanding APOL1-mediated kidney disease. Recent medical research has identified specific genetic variations that substantially impact kidney health in the African American community.

Those who have variants in both copies of the APOL1 gene have a 1 in 5 chance of developing kidney disease. "A lot of people don't even know about how prevalent the APOL1 gene is in the African ...

The inaugural APOL1-mediated Kidney Disease Awareness Day represents a significant milestone in these efforts, bringing together medical professionals, community leaders, ...

This type of kidney disease can develop even at a young age, and it can advance faster than other kidney diseases. “The link between APOL1 gene variants and kidney disease was discovered just 15 ...

Maze Therapeutics has initiated the HORIZON Study, a Phase 2 trial evaluating MZE829 for APOL1 kidney disease treatment. Quiver AI Summary. Maze Therapeutics, a clinical-stage biopharmaceutical ...

"Our study provides data about West Africans that will help us better understand the risk of chronic kidney disease associated with APOL1 variants," said Adebowale A. Adeyemo, M.B.B.S., who is a ...

The study found that nearly one-third of individuals in these two West African nations carry APOL1 variants that increase the risk of chronic kidney disease.While these APOL1 variants are seen most ...

MZE829, an oral APOL1 inhibitor, is being investigated as a novel treatment for AKD, which is a subset of chronic kidney disease. The HORIZON Study is an open-label trial designed to include a ...

Maze Therapeutics, a kidney disease therapy developer, recently IPO-ed with a market cap of $487mn and significant early-stage investor backing. Lead asset MZE829 targets APOL1 Kidney Disease ...

MISSION, Kan., April 21, 2025 /PRNewswire/ -- (Family Features) Senior year of high school is a time for big changes for most people, but for Emani McConnell-Brent, she did not expect it would ...